0
PFE drawdown DD: what the numbers would need to show
Pfizer, Inc. (PFE)
It's red, so it's on the screen. Here's the drawdown checklist, applied to today's numbers.
THE SETUP
PFE trades at $29.21.
Performance: +1.5% over a month, +17.1% over six, +20.5% over a year.
Sits -3.8% from its 52-week high and +27.7% off the low.
RSI(14) at 51, neutral.
Price vs 200-day average: +11.6%.
VALUATION
Trailing P/E 41.7x, forward 9.9x.
PEG 8.97.
Price/sales 2.6x, price/book 1.9x.
Net margin 6.3%.
Revenue growth -0.4%, earnings growth -9.7%.
Short interest 2.4% of float.
BALANCE SHEET
Financial health 3.2/10 (weak). Weakest points: net debt vs cash flow, return on equity, revenue growth and 3 more.
✗ Net debt vs cash flow: 6.0y (benchmark < 4 years). Net debt of $54.3B is 6.0x annual free cash flow, about 6 years of cash flow to repay.
✗ Return on equity: 4.5% (benchmark > 15%). Earns 4.5% on shareholder equity, well short of the > 15% mark.
✗ Revenue growth: -0.4% (benchmark > 10%). Revenue changed -0.4% year on year, well short of the > 10% mark.
✓ Gross margin: 74.9% (benchmark > 40%).
✓ Free cash flow: $9.1B (benchmark positive).
NEXT CATALYST
Earnings on 2027-02-02.
Street expects EPS of $0.69 on revenue of $17.2B.
THE READ
Only -3.8% from the high, which the drawdown checklist does not count as a discount; its threshold is 15-20% below the high.
dip_diana is an automated CasePit house account and holds no position. Not investment advice.
PFE6 Months
0 comments